Incidence of ITP exacerbation* after sample stratification by history of splenectomy and number of prior medical therapies or history of rituximab use
| . | First vaccine dose . | Second vaccine dose . | ||||
|---|---|---|---|---|---|---|
| . | n . | ITP exacerbation (n) . | ITP exacerbation (%) . | n . | ITP exacerbation (n) . | ITP exacerbation (%) . |
| Splenectomy, 0-4 prior therapies | 7 | 2 | 28.6 | 6 | 1 | 16.7 |
| Splenectomy, ≥5 prior therapies | 10 | 6 | 60 | 9 | 4 | 44.4 |
| No splenectomy, 0-4 prior therapies | 47 | 1 | 2.1 | 37 | 6 | 16.2 |
| No splenectomy, ≥5 prior therapies | 6 | 3 | 50 | 3 | 1 | 33.3 |
| Splenectomy, no prior rituximab | 6 | 3 | 50 | 5 | 2 | 40 |
| Splenectomy + prior rituximab | 17 | 8 | 47.1 | 13 | 5 | 38.5 |
| No splenectomy, no prior rituximab | 50 | 3 | 6 | 28 | 3 | 10.7 |
| No splenectomy + prior rituximab | 22 | 2 | 9.1 | 14 | 4 | 28.6 |
| . | First vaccine dose . | Second vaccine dose . | ||||
|---|---|---|---|---|---|---|
| . | n . | ITP exacerbation (n) . | ITP exacerbation (%) . | n . | ITP exacerbation (n) . | ITP exacerbation (%) . |
| Splenectomy, 0-4 prior therapies | 7 | 2 | 28.6 | 6 | 1 | 16.7 |
| Splenectomy, ≥5 prior therapies | 10 | 6 | 60 | 9 | 4 | 44.4 |
| No splenectomy, 0-4 prior therapies | 47 | 1 | 2.1 | 37 | 6 | 16.2 |
| No splenectomy, ≥5 prior therapies | 6 | 3 | 50 | 3 | 1 | 33.3 |
| Splenectomy, no prior rituximab | 6 | 3 | 50 | 5 | 2 | 40 |
| Splenectomy + prior rituximab | 17 | 8 | 47.1 | 13 | 5 | 38.5 |
| No splenectomy, no prior rituximab | 50 | 3 | 6 | 28 | 3 | 10.7 |
| No splenectomy + prior rituximab | 22 | 2 | 9.1 | 14 | 4 | 28.6 |
Defined as development of any 1 or more of the following: (a) ≥50% decline in platelet count from prevaccination baseline; (b) >20% decline from prevaccination baseline and platelet nadir <30 ×109/L; and/or (c) receipt of rescue therapy for ITP.